PharmAthene, Inc s in-depth stock price analysis indicates that the stock price has dropped -62.95% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -56.37% . Looking at the past 52 week period, the stock price is down -28.48% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of PharmAthene, Inc has a positive value of 71.96 compared to overall market. PharmAthene, Inc (NYSEMKT:PIP) has tumbled 65.76% during the past week and has dropped 66.77% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 66.03%. PharmAthene, Inc (NYSEMKT:PIP) has underperformed the index by 67.36% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
PharmAthene, Inc (NYSEMKT:PIP) : On Friday heightened volatility was witnessed in PharmAthene, Inc (NYSEMKT:PIP) which led to swings in the share price. The stock opened for trading at $1.01 and hit $1.2 on the upside , eventually ending the session at $1.13, with a gain of 11.88% or 0.12 points. The heightened volatility saw the trading volume jump to 11,572,473 shares. The 52-week high of the share price is $3.5 and the company has a market cap of $78 million. The 52-week low of the share price is at $0.47 .
Company has reported several Insider transactions to the SEC, on Apr 15, 2016, Eric I Richman (director) sold 329,354 shares at 2.20 per share price.On Mar 23, 2015, Peter Steven St (director) purchased 25,000 shares at 1.65 per share price.On Jan 9, 2015, Linda L Chang (SVP, CFO & Secretary) sold 29,600 shares at 2.10 per share price.
PharmAthene Inc. is a biodefense company formed to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. PharmAthenes lead programs include Valortim and Protexia.